Blood test found early signs of future relapsing MS

Credibility

Interest

Share:1 min read

Key Takeaway

A blood test found higher levels of certain antibodies years before people were diagnosed with relapsing MS.

What They Found

Researchers measured antibodies (proteins made by the immune system) that respond to part of the Epstein-Barr virus. Levels were higher in people who later received an MS diagnosis than in people who did not. The difference appeared as early as nine months after the virus first showed up in blood tests. That was about five years before the MS diagnosis for the middle person in the group. People whose antibody levels stayed high were diagnosed sooner after the virus first showed up in blood tests.

Who Should Care and Why

The study compared people with relapsing-remitting MS and matched people without MS. Researchers used blood samples collected over time, starting when the Epstein-Barr virus first showed up in blood tests. They looked for an early blood sign of MS risk. Higher levels of the antibodies they measured were linked to a later MS diagnosis. The findings may help researchers study who is more likely to develop MS.

Important Considerations

You should know this study compared 324 people with relapsing-remitting MS and 324 matched people without MS. It found a link between antibody levels and later diagnosis, but did not show that this blood test can predict your future. The abstract does not say how well the test would work for someone outside these groups.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Nature communications often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News